SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare?

Shares of Summit Therapeutics (SMMT) jumped in after-hours trading on Monday after AstraZeneca agreed to put $2 billion into the cancer-drug developer, sending the stock as much as 19% above its regular close.AZN-SMMT Deal: A Premium Stake, Not A BuyoutAstraZeneca will buy newly issued convertible…